The FDA granted a third breakthrough therapy designation to Pharmacyclics and Janssen Biotech's experimental oral agent ibrutinib as a treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short arm of chromosome 17. The designation was based on positive data from preclinical and clinical trials.

Related Summaries